(UTHR) United Therapeutics - Ratings and Ratios
Treprostinil, Treprostinil, Treprostinil, Tadalafil, Dinutuximab
UTHR EPS (Earnings per Share)
UTHR Revenue
Description: UTHR United Therapeutics
United Therapeutics (NASDAQ: UTHR) is a U.S.-based biotech that focuses on products for chronic, life-threatening conditions, chiefly pulmonary arterial hypertension (PAH) and high-risk neuroblastoma. Its current commercial portfolio includes inhaled Tyvaso (dry-powder and solution), the treprostinil injection Remodulin, the oral tablet Orenitram, the PDE-5 inhibitor Adcirca, and the monoclonal antibody Unituxin for neuroblastoma, plus the Remunity infusion pump.
The pipeline extends beyond the core PAH franchise: RemoPro (an oral treprostinil), the selective prostacyclin receptor agonist Ralinepag (in partnership with Arena Pharmaceuticals), Aurora-GT gene-therapy for vascular remodeling, nebulized Tyvaso for idiopathic pulmonary fibrosis, and early-stage xenograft organ products. Strategic collaborations with DEKA (sub-cutaneous delivery system), MannKind (inhalation powder and Dreamboat device), and Arena broaden both development capacity and commercialization reach.
Key financial and market metrics (FY 2023): revenue of $2.0 billion, driven > 70 % by PAH products; cash and short-term investments of $1.3 billion, providing a runway of ≈ 3 years at current burn; and a net loss of $140 million, reflecting heavy R&D spend. The global PAH market is projected to grow at a CAGR of ~6 % to exceed $5 billion by 2028, while the neuroblastoma segment benefits from increasing pediatric oncology funding and favorable reimbursement trends.
Given the company’s cash position, pipeline diversification, and exposure to a growing specialty-therapy market, analysts should monitor FDA decision dates for RemoPro and Aurora-GT, as well as the commercial uptake of the inhaled Tyvaso DPI, which could materially shift revenue mix.
For a deeper quantitative assessment of UTHR’s valuation metrics, you may find ValueRay’s analyst toolkit useful.
UTHR Stock Overview
| Market Cap in USD | 19,900m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1999-06-17 |
UTHR Stock Ratings
| Growth Rating | 61.4% |
| Fundamental | 85.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 3.51% |
| Analyst Rating | 4.0 of 5 |
UTHR Dividends
Currently no dividends paidUTHR Growth Ratios
| Growth Correlation 3m | 94% |
| Growth Correlation 12m | -19.4% |
| Growth Correlation 5y | 89.9% |
| CAGR 5y | 26.17% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.79 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.88 |
| Sharpe Ratio 12m | -0.02 |
| Alpha | 8.53 |
| Beta | 0.662 |
| Volatility | 31.94% |
| Current Volume | 658.8k |
| Average Volume 20d | 724.6k |
| Stop Loss | 417.3 (-3.4%) |
| Signal | 0.27 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (1.24b TTM) > 0 and > 6% of Revenue (6% = 184.7m TTM) |
| FCFTA 0.14 (>2.0%) and ΔFCFTA 0.49pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 107.2% (prev 106.5%; Δ 0.70pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.17 (>3.0%) and CFO 1.37b > Net Income 1.24b (YES >=105%, WARN >=100%) |
| Net Debt (-1.59b) to EBITDA (1.66b) ratio: -0.96 <= 3.0 (WARN <= 3.5) |
| Current Ratio 7.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (48.3m) change vs 12m ago 1.68% (target <= -2.0% for YES) |
| Gross Margin 88.98% (prev 88.85%; Δ 0.13pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 42.07% (prev 38.92%; Δ 3.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 52.11 (EBITDA TTM 1.66b / Interest Expense TTM 31.4m) >= 6 (WARN >= 3) |
Altman Z'' 18.71
| (A) 0.42 = (Total Current Assets 3.83b - Total Current Liabilities 527.1m) / Total Assets 7.91b |
| (B) 0.99 = Retained Earnings (Balance) 7.85b / Total Assets 7.91b |
| warn (B) unusual magnitude: 0.99 — check mapping/units |
| (C) 0.22 = EBIT TTM 1.64b / Avg Total Assets 7.32b |
| (D) 10.70 = Book Value of Equity 7.85b / Total Liabilities 734.4m |
| Total Rating: 18.71 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.52
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 6.24% = 3.12 |
| 3. FCF Margin 34.80% = 7.50 |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda -0.96 = 2.50 |
| 6. ROIC - WACC (= 9.73)% = 12.17 |
| 7. RoE 18.73% = 1.56 |
| 8. Rev. Trend 97.19% = 7.29 |
| 9. EPS Trend -22.44% = -1.12 |
What is the price of UTHR shares?
Over the past week, the price has changed by -3.73%, over one month by +7.21%, over three months by +47.38% and over the past year by +20.20%.
Is United Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UTHR is around 457.91 USD . This means that UTHR is currently overvalued and has a potential downside of 5.95%.
Is UTHR a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the UTHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 492.9 | 14% |
| Analysts Target Price | 492.9 | 14% |
| ValueRay Target Price | 509.9 | 18% |
Last update: 2025-10-11 05:04
UTHR Fundamental Data Overview
P/E Trailing = 17.1808
P/E Forward = 15.2905
P/S = 6.4655
P/B = 2.7957
P/EG = 1.4347
Beta = 0.662
Revenue TTM = 3.08b USD
EBIT TTM = 1.64b USD
EBITDA TTM = 1.66b USD
Long Term Debt = unknown (none)
Short Term Debt = 300.0m USD (from shortTermDebt, last fiscal year)
Debt = 300.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -1.59b USD (from netDebt column, last quarter)
Enterprise Value = 17.15b USD (19.90b + Debt 300.0m - CCE 3.05b)
Interest Coverage Ratio = 52.11 (Ebit TTM 1.64b / Interest Expense TTM 31.4m)
FCF Yield = 6.24% (FCF TTM 1.07b / Enterprise Value 17.15b)
FCF Margin = 34.80% (FCF TTM 1.07b / Revenue TTM 3.08b)
Net Margin = 40.36% (Net Income TTM 1.24b / Revenue TTM 3.08b)
Gross Margin = 88.98% ((Revenue TTM 3.08b - Cost of Revenue TTM 339.1m) / Revenue TTM)
Gross Margin QoQ = 89.03% (prev 88.36%)
Tobins Q-Ratio = 2.17 (Enterprise Value 17.15b / Total Assets 7.91b)
Interest Expense / Debt = 2.43% (Interest Expense 7.30m / Debt 300.0m)
Taxrate = 24.22% (98.9m / 408.4m)
NOPAT = 1.24b (EBIT 1.64b * (1 - 24.22%))
Current Ratio = 7.26 (Total Current Assets 3.83b / Total Current Liabilities 527.1m)
Debt / Equity = 0.04 (Debt 300.0m / totalStockholderEquity, last quarter 7.17b)
Debt / EBITDA = -0.96 (Net Debt -1.59b / EBITDA 1.66b)
Debt / FCF = -1.49 (Net Debt -1.59b / FCF TTM 1.07b)
Total Stockholder Equity = 6.63b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.71% (Net Income 1.24b / Total Assets 7.91b)
RoE = 18.73% (Net Income TTM 1.24b / Total Stockholder Equity 6.63b)
RoCE = 22.17% (EBIT 1.64b / Capital Employed (Total Assets 7.91b - Current Liab 527.1m))
RoIC = 18.08% (NOPAT 1.24b / Invested Capital 6.86b)
WACC = 8.35% (E(19.90b)/V(20.20b) * Re(8.45%) + D(300.0m)/V(20.20b) * Rd(2.43%) * (1-Tc(0.24)))
Discount Rate = 8.45% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.52%
[DCF Debug] Terminal Value 79.56% ; FCFE base≈993.8m ; Y1≈1.18b ; Y5≈1.83b
Fair Price DCF = 641.7 (DCF Value 29.02b / Shares Outstanding 45.2m; 5y FCF grow 19.75% → 3.0% )
EPS Correlation: -22.44 | EPS CAGR: -47.08% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.19 | Revenue CAGR: 17.21% | SUE: -0.00 | # QB: 0
Additional Sources for UTHR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle